Andere Sprachen aTyr Pharma, Inc.

Aktien

A2PM86

US0021202025

LIFE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
1.6 ^USD	-1.23%		+0.63%	+13.48%

15.03.	ATYR PHARMA, INC. : RBC Capital Markets bekräftigt seine Kaufempfehlung	ZM
14.03.	Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

ATyr Pharma to Participate in April Investor Conferences	01.04.
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14.03.
Atyr Pharma: Q4 Earnings Snapshot	14.03.
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update	14.03.
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14.03.
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results	28.02.
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants	21.02.
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis	21.02.
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity	29.01.
ATyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor	18.01.
ATyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023	13.11.
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09.11.
Atyr Pharma: Q3 Earnings Snapshot	09.11.
ATyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update	09.11.
Earnings Flash (LIFE) ATYR PHARMA Posts Q3 Revenue $353,000	09.11.
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD	01.11.
ATyr Pharma to Present at November Investor Conferences	01.11.
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD	31.10.23
Atyr Pharma, Inc. Announces Dosing of First Patient in Phase 2 Efzo-Connect?? Study of Efzofitimod in Patients with Ssc-Ild	31.10.23
Top Premarket Gainers	04.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen aTyr Pharma, Inc.

Aktien

A2PM86

US0021202025

LIFE

Andere Sprachen

Filter